Aim: Monocrotaline (MCT) in plants of the genus Crotalaria induces significant toxicity in multiple organs including the liver, lung and kidney. Metabolic activation of MCT is required for MCT-induced toxicity. In this study, we attempted to determine whether the toxicity of MCT in kidney was a consequence of the metabolic activation of MCT in the liver. Methods: Liver-specific cytochrome P450 reductase-null (Null) mice, wild-type (WT) mice and CYP3A inhibitor ketoconazole-pretreated WT (KET-WT) mice were examined. The mice were injected with MCT (300, 400, or 500 mg/kg, ip), and hepatotoxicity and nephrotoxicity were examined 24 h after MCT treatment. The levels of MCT and its metabolites in the blood, liver, lung, kidney and bile were determined using LC-MS analysis. Results: Treatment of WT mice with MCT increased the serum levels of alanine aminotransferase, hyaluronic acid, urea nitrogen and creatinine in a dose-dependent manner. Histological examination revealed that MCT (500 mg/kg) caused severe liver injury and moderate kidney injury. In contrast, these pathological abnormalities were absent in Null and KET-WT mice. After injection of MCT (400 and 500 mg/kg), the plasma, liver, kidney and lung of WT mice had significantly lower MCT levels and much higher N-oxide metabolites contents in compared with those of Null and KET-WT mice. Furthermore, WT mice had considerably higher levels of tissue-bound pyrroles and bile GSH-conjugated MCT metabolites compared with Null and KET-WT mice. Conclusion: Cytochrome P450s in mouse liver play a major role in the metabolic activation of MCT and thus contribute to MCT-induced renal toxicity.
Introduction
Pyrrolizidine alkaloids (PAs) are naturally occurring phytochemicals that are common constituents of hundreds of plant species around the world. PA-containing plants are likely the most common poisonous plants affecting livestock, wildlife, and humans [1] . Human exposure occurs through the consumption of PA-contaminated food or herbal medicines [2] . As recently as 1995, approximately 6000 people worldwide became victims of PA-induced toxicity [3] . A representative PAs toxin, monocrotaline (MCT), exists in plants of the genus Crotalaria and can cause injuries to hepatocytes, liver sinusoidal endothelial cells (LSECs), kidneys, and lungs [4] [5] [6] [7] . Metabolic activation is required for MCT-induced toxicity [8] . In general, there are three major metabolic pathways of MCT, N-oxidation, hydrolysis, and dehydrogenation ( Figure 1 ) [1] . The metabolite produced in the final step, dehydromonocrotaline (DHM), is believed to be responsible for MCT toxicity [9, 10] . DHM is highly active and can react with water to form a less toxic but relatively stable metabolite, 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP) [11] . These two metabolites can either rapidly form bound pyrroles by reacting with other cellular macromolecules, leading to toxicity, or react with glutathione (GSH) to form GSH conjugates including 7-glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (GSH-DHP) and 7,9-diglutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (diGSH-DHP) [12] [13] [14] . Hepatic cytochrome P450s, such as CYP3A, CYP2B and CYP2C, are involved in the metabolic activation and hepatotoxicity and pneumotoxicity of MCT [1] . However, the precise role of hepatic metabolic activation of MCT in MCTinduced renal toxicity has not been well established. Cytochrome P450s are the most important xenobiotic-metabolizing enzymes and participate in the metabolism of most foreign www.chinaphar.com Yao J et al Acta Pharmacologica Sinica npg chemicals [15] . In addition to the abundant cytochrome P450s in the liver, it is believed that various extrahepatic cytochrome P450s also contribute to xenobiotic biotransformation [16] . A unique mouse model has been developed in which the cytochrome P450 reductase (Cpr) gene encoding the obligate redox partner for all microsomal cytochrome P450s is deleted specifically in hepatocytes, resulting in the loss of ~95% of microsomal activity in hepatocytes. Such mice are called liverCpr-null (Null) mice [17] . Recently, this model has been used in a number of studies to investigate the role of hepatic metabolism in the extrahepatic toxicity of chemicals or drugs [18, 19] . Using this unique mouse model together with a pharmacologic inhibition method, we found that MCT-induced apoptosis of renal tubular cells and LSEC injury are dependent on hepatic cytochrome P450s. Further pharmacokinetic analysis showed that hepatic P450s contribute to the clearance and distribution of MCT and its metabolites in the kidney. Thus, we provide the evidence that hepatic cytochrome P450-mediated metabolic activation plays a critical role in MCT-induced kidney toxicity.
Materials and methods

Materials
MCT and retrorsine (RTS) were purchased from Sigma (St Louis, MO, USA). GSH was purchased from Beyotime (Haimen, China). GSH-DHP and diGSH-DHP were obtained by o-chloranil oxidation of MCT to DHM with limited or excess amounts of GSH, respectively [20, 21] . Monocrotaline N-oxide (MNO) and retronecine (RET) were prepared as previously described [22, 23] . All other chemicals were of reagent grade and commercially available; they were purchased from Sinopharm (Shanghai, China).
Animal treatments
Null mice were a gift from Dr Xing-xing DING (Wadsworth Center, Albany, NY, USA). Protocols for animal breeding and genotyping were reported previously [24] . Two-to four-monthold male mice from Null and WT littermate groups of mixed C57BL/6 and 129/Sv genetic backgrounds were used in these studies. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Shanghai Institute of Materia Medica (Shanghai, China). Animals were maintained at 22 °C with a 12-h on and 12-h off light cycle.
Toxicological studies
Mice were treated with a single intraperitoneal injection of MCT at 300, 400, and 500 mg/kg or saline as a control. In the KET-pretreated group, KET, as a suspension in 0.5% sodium carboxyl methyl cellulose (CMC-Na), was administered twice orally at a dose of 70 mg/kg, once at 18 h and the other 1 h before the administration of MCT. Mice were euthanized 24 h after administration of MCT. After drawing blood samples via cardiac puncture, the liver and kidneys were collected promptly and processed according to standard pathology Figure 1 . Scheme of the metabolic pathway of monocrotaline (MCT). MCT is mainly metabolized in three pathways. The detoxification pathways include hydrolysis by carboxylesterase to form retronecine and N-oxidation by FMO and CYP450s to form monocrotaline N-oxide (MNO). The metabolic activation of MCT occurs via dehydrogenation primarily, by CYP3A4 and CYP2B6, to form dehydromonocrotaline (DHM), which is highly active. It can react with water to form DHP and conjugate with nucleophiles to form adducts such as GSH-DHP, diGSH-DHP, and bound pyrroles.
procedures [19] . Sections (5 μm thick) were stained with hematoxylin and eosin. For semiquantitative assessment of kidney injury, the severity of kidney lesions was graded as previously described (++, severe; + moderate; ±, mild; -, negative) [24] . The serum levels of blood alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine were determined with an automatic HITACHI Clinical Analyzer Model 7080 (Hitachi, Tokyo, Japan). The concentration of hyaluronic acid (HA) in the serum was measured with an ELISA kit (Shanghai Xitang Biotechnology Co, Shanghai, China) according to the manufacturer's instructions.
Toxicokinetics studies
Mice were treated with a single intraperitoneal injection of MCT at 400 or 500 mg/kg. To determine the levels of MCT and its metabolites in the plasma, the blood samples were collected in heparin-coated capillaries by tail bleeding at 10 min, 30 min, and 1, 2, 4, 8, 12, or 24 h after dosing. Following centrifugation at 4000×g for 5 min at 4 °C, the plasma was transferred to a clean tube and kept at -80 °C until analysis. To determine the tissue distribution of MCT and its metabolites, the animals were sacrificed 1 h after MCT administration. Tissues, including the liver, kidney, and lung, were collected and homogenized in double-distilled H 2 O (4 mL/g tissue). The homogenate was separated by centrifugation at 18 000×g for 10 min; the pellets were discarded, and the supernatants were frozen at -80 °C until use. For determination of GSH conjugates, bile was collected at 10 min, 30 min, and 1, 2, 3, 4, 5, or 6 h after MCT treatment via bile duct cannulation.
Sample treatment for liquid chromatography-mass spectrometry (LC-MS) analysis
Plasma and tissue homogenates were thawed and vortexed for 10 s. RTS was added to the samples as an internal standard, and 20% NH 3 -H 2 O was then added, followed by extraction with n-butanol. The extraction was dried using a centrifugal vacuum concentrator. The residue was reconstituted into 100 μL of 15% methanol in mobile phase A (5 mmol/L ammonium acetate with 0.1% acetic acid), vortexed, and centrifuged at 18 000×g for 5 min. The supernatant was then transferred to vials, and 20 μL was injected into the column for LC-MS/MS analysis.
Bile samples were mixed with 3 volumes of methanol and spun at 18 000×g for 5 min. The supernatants were mixed with 4 volumes of mobile phase A, filtered with a disposable filter unit, and analyzed by LC-MS/MS.
LC-MS/MS and operating conditions
The quantification of MCT and its metabolites was performed on an HPLC-ESI-MS system (Shimadzu LCMS-2010EV, Tokyo, Japan). Separation was performed on a Waters symmetry C18 column. Mobile phases A and B (acetonitrile) were used with gradient elution as follows: 0-8 min, 95%-40% A; 8-9 min, 40%-95% A; 9-12 min, 95% A. The flow rate was 0.2 mL/min. Positive electrospray ionization and multiple reaction monitoring (MRM) were performed to simultaneously monitor MCT, MNO, RTS, and RET ions at m/z 326/120, 342/137, 352/120, and 156/80, respectively. GSH-DHP and diGSH-DHP were analyzed in the negative electrospray ionization mode with selected ion monitoring (SIM) at m/z 441 and 730, respectively. Interface voltage was 4.5 kV. The desolvation line and heat block temperatures were set at 250 °C and 400 °C. The nebulization gas was set to 3 L/h with the cone gas at 50 L/h. The detector voltage was set at 1.72 kV.
For MCT, the lower limit of quantification (LLOQ) was 5 ng/mL in the plasma, liver, kidney and lung. The intra-and inter-day precisions as assessed by the relative standard deviation (RSD) were less than 10.44% and 12.49%, respectively, for plasma samples, 8.51% and 9.74% for liver samples, 9.41% and 9.02% for kidney samples, and 10.62% and 11.7% for lung samples. The mean extraction recoveries were no less than 93.17%, 95.17%, 96.02%, and 97.11% for plasma, liver, kidney and lung samples, respectively.
For MNO, the LLOQ was 5 ng/mL in the plasma, liver, kidney and lung. The intra-and inter-day precisions assessed using the RSD were less than 11.02% and 7.92% for plasma samples, 8.55% and 9.72% for liver samples, 8.13% and 10.05% for kidney samples, and 7.04% and 8.95% for lung samples, respectively. The mean extraction recoveries were no less than 70.23%, 73.12%, 74.83%, and 75.51% for plasma, liver, kidney and lung samples, respectively.
For RET, the LLOQ was 40 ng/mL in the plasma, liver, kidney and lung. The intra-and inter-day precisions were less than 7.11% and 13.20% for plasma samples, 9.12% and 12.77% for liver samples, 9.47% and 13.87% for kidney samples, and 8.25% and 10.38% for lung samples, respectively. The mean extraction recoveries were no less than 56.17%, 58.02%, 58.8%, and 60.7% for plasma, liver, kidney and lung samples, respectively.
Determination of tissue-bound pyrroles
Total tissue-bound pyrroles were estimated by modification of a reported method [13] . Briefly, the samples were homogenized in 5 volumes of acetone and centrifuged at 900×g for 5 min. After washing with absolute ethanol, the pellets were reconstituted in 5 volumes of 2% acidic silver nitrate ethanol solution and shaken for 30 min followed by centrifugation. The resulting supernatant was reacted with 4-dimethylaminobenzaldehyde (v/v 4:1) in ethanol containing 1% perchloric acid at 55 °C for 10 min. The absorbance of the sample was measured at both 562 and 625 nm. Adjusted absorbance (A) was determined as A=1.1 (A 562 nm -A 625 nm ). The concentration of bound pyrroles was calculated using a molar absorptivity of 60 000.
Statistical analysis
Data are presented as the mean±SD, and significant differences were identified by Student's t-test or one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. Differences were considered significant at P<0.05.
Results
Abolished hepatic and renal toxicity of MCT in Null and KET-WT mice MCT-induced toxicity was examined in Null, WT, and KET-WT mice 24 h after a single intraperitoneal injection at 300, 400, or 500 mg/kg. Serum biochemical analysis showed dosedependent increases in serum levels of ALT, HA (a specific marker for endothelial cell injury), BUN and Cre in WT mice after treatment, whereas no changes were observed in Null and KET-WT mice (Figure 2 ). Histologically, 24 h after 500 mg/kg MCT injection, WT mice developed severe liver injury, such as hepatocyte necrosis, endothelial cell detachment, and severe hemorrhage ( Figure 3A) , and moderate kidney injury, which was characterized by renal tubular cell apoptosis (Figure 3B) . However, no lesions were observed in the liver and kidney of Null or KET-WT mice (Figure 3C-3F) . The severity Increased plasma content and tissue distribution of MCT in Null and KET-WT mice The contribution of hepatic P450s to MCT metabolism was investigated in vivo by comparing the plasma and tissue contents of MCT among WT, Null, and KET-WT mice after a single intraperitoneal injection of MCT at 400 or 500 mg/kg. Typical LC/MS chromatograms are shown in Figure 4 . Compared with WT mice, there was a significant increase in the plasma MCT levels of Null and KET-WT mice at 1 and 2 h after treatment with MCT ( Figure 5A , 5B). The area under the curve (AUC) of plasma MCT in Null and KET-WT mice was markedly higher than that in WT mice ( Table 2 ). The tissue MCT levels showed that, compared with WT mice, the MCT levels markedly increased in the liver, kidney and lung of Null and KET-WT mice 1 h after dosing ( Figure 5C, 5D ). Taken together, these results suggest that the inactivation of hepatic P450 or KET pretreatment compromised the metabolism of MCT in vivo.
Diminished levels of MNO and increased levels of RET in Null and KET-WT mice MNO and RET are important detoxified metabolites of MCT.
To examine whether decreased MCT toxicity in Null and KET-WT mice was correlated with changes in the contents of these npg metabolites, we determined the levels of MNO and RET in the plasma and tissues of mice treated with MCT at 400 and 500 mg/kg. We found that plasma MNO levels were significantly lower in Null and KET-WT mice than in WT mice at time points ranging from 30 min to 2 h ( Figure 6A, 6B) . Similarly, the levels of MNO in the liver, kidney, and lung of Null and KET-WT mice were significantly decreased compared with WT mice (Figure 6E, 6F ). As shown in Table 2 , there was a significant decrease in the C max and AUC of MNO in Null and KET-WT mice compared to those in WT mice. The plasma RET levels were significantly higher in Null and KET-WT mice at 30 min and 1 h after MCT administration compared to those in WT mice ( Figure 6C, 6D) . Unexpectedly, RET levels in tissues could not be detected in our test conditions, possibly because the RET contents may have been below the detection limit.
Inhibition of metabolic activation of MCT in Null and KET-WT mice
The toxicity of MCT is associated with the toxic metabolites DHM and DHP. However, they are very reactive and easily form adducts with endogenous nucleophilic macromolecules.
To examine the metabolic activation of MCT, we determined the levels of DHP adducts including GSH-DHP, diGSH-DHP, and tissue-bound pyrroles in mice after a single intraperitoneal injection of MCT at 400 or 500 mg/kg. Compared with WT mice, the amount of tissue-bound pyrroles decreased significantly in the liver, kidney and lung of Null and KET-WT mice 1 h after treatment with MCT ( Figure 7A, 7B ), accompanied by a marked decrease in the levels of bile GSH-DHP and diGSH-DHP from 30 min to 2 h ( Figure 7C-7F) . Consistent with these results, the AUCs of GSH-DHP and diGSH-DHP were significantly lower in Null and KET-WT mice ( Table 2 ). Notice- Figure 7 . The levels of tissue-bound pyrroles and bile GSH-DHP and diGSH-DHP in WT, Null, and KET-WT mice. The tissues were collected from mice at 1 h after a single injection of MCT at 400 or 500 mg/kg. Bound pyrrole levels in the liver, kidney and lung 1 h after treatment with 400 (A) or 500 mg/kg MCT (B). GSH-DHP in the bile at various time points after treatment with 400 (C) or 500 mg/kg MCT (D). diGSH-DHP levels in the bile at various time points after treatment with 400 (E) or 500 mg/kg MCT (F 
Discussion
The ingestion of MCT causes intra-and extrahepatic toxicity after metabolic activation of MCT. It has been reported that MCT-induced pneumotoxicity is tightly linked to metabolic activation in the liver, based on studies of in vitro and ex vivo perfusion [9, 25] . Here, we provide direct evidence that hepatocyte P450s play a critical role in the production of active metabolites in the extrahepatic tissues of mice. Furthermore, we demonstrated that liver-specific P450s are responsible for MCT-induced injury to the kidney as well as LSECs.
Dehydrogenation is an essential metabolic activation step for the rapid clearance of MCT in vivo [1] . The inactivation of hepatic cytochrome P450s totally abolished MCT-induced toxicity, which strongly suggests a major role of hepatic cytochrome P450s in the metabolic activation and toxicity of MCT. Cyp3a, Cyp2b, and Cyp2c have been reported to be involved in the metabolic activation of MCT [1] . In sheep, hamsters and guinea pigs, Cyp2b and Cyp2c play a role in the bioactivation of MCT [1] , while in rats and mice, multiple studies have shown a major role for Cyp3a in the formation of reactive pyrroles [25] [26] [27] [28] . Anti-Cyp3a antibody almost completely inhibits the formation of reactive pyrroles (94% inhibition) [25] . In this study, as a highly selective inhibitor of Cyp3a [29] , KET, markedly suppressed the metabolic activation and toxicity of MCT. Taken together, these data suggest that hepatic Cyp3a, the most abundant isoenzyme of cytochrome P450s in the liver [30] , may play a major role in the metabolic activation and toxicity of MCT.
In contrast to a previous report that MCT induces nephrotoxicity, as demonstrated by necrotic changes in the glomeruli and hemosiderin granules in tubular epithelial cells, as well as focal endothelial cell detachment [31, 32] , we found that MCT caused apoptosis of renal tubular cells in WT mice ( Figure 2B ). This disparity might be due to differences in species, route of MCT administration or sampling time. In Null mice, LSEC injury was abolished ( Figure 2B, 3E) , indicating that the metabolic activation of MCT in hepatocytes was responsible for MCT-induced LSECs toxicity. Moreover, the higher sensitivity of LSECs to MCT may be explained by the low capacity of these cells to synthesize GSH, which results in reduced GSH detoxification [33] . In our study, the dramatically decreased levels of bound pyrroles in the kidneys of Null mice indicated that the bioactivation of MCT in liver contributes to the production of bound pyrroles in the kidneys. This point is supported by a report that DHM and DHP, highly reactive metabolites of MCT, can reach extrahepatic tissues such as the kidney and lung [34] . Several previous studies have reported that treatment with a CYP3A inhibitor cannot completely abolish the bioactivation of PAs [35, 36] . Similarly, in our study, bound pyrroles in the liver and kidney were not totally abolished in KET-WT mice, which could be attributed to the incomplete inhibition of Cyp3a in hepatocytes by KET. Likewise, the inactivation of hepatic P450s in Null mice did not totally abolish the formation of GSH conjugates and bound pyrroles, which may be for the following reasons: (1) In Null mice, Cpr knockout does not completely abolish the microsomal activity; approximately 5% microsomal activity remains, with cytochrome b5 as the electron donor [37, 38] . (2) Kidney microsomes also have the capacity to metabolically activate PAs [36] . (3) Cyp3a, which is abundant in the small intestine, may also be implicated in the generation of active metabolites in the liver and kidney in Null mice [39] . MNO and RET are important detoxified metabolites of MCT. The plasma and tissue levels of MNO were markedly decreased in Null mice, indicating that hepatic P450s greatly contributed to the production of MNO. Similarly, the levels of MNO were significantly decreased in KET-WT mice (Figure 6A, 6C ). Considering the importance of Cyp3a in the N-oxidation of PAs [1] , our results suggest that hepatic Cyp3a might play an important role in N-oxidation of MCT in vivo. The increases in the plasma levels of RET in KET-WT and Null mice might be due to the increased processing of MCT by enzymes such as carboxylesterase.
In summary, hepatic P450s play an important role in the metabolism and toxicity of MCT in vivo. Because considerable polymorphisms of cytochrome P450s have been observed in humans [40] , our results suggest that populations with higher cytochrome P450 activities, especially CYP3A, may have a higher risk for toxicity induced by MCT or other PAs. Our findings provide new insights into the mechanisms of MCTinduced LSEC damage and nephrotoxicity and possible new approaches for the treatment or prevention of PA-induced toxicity.
